Who Produces Wegovy and Why It Matters for UK Patients

You're researching the pen in someone's hand at the gym, here's the factual answer

Wegovy has been showing up in gyms, staff rooms and social media feeds across the UK, and people naturally want to know who actually makes it. The answer is Novo Nordisk, a Danish company founded in 1923 that has specialised in metabolic and hormonal medicines for a century. Semaglutide, the active compound inside Wegovy, was developed by their research teams and went through extensive clinical trials before reaching regulators. In the UK, the MHRA assessed the evidence and granted the marketing authorisation, a process separate from, and independent of, any European approval.

Novo Nordisk manufactures Wegovy at licensed production facilities and supplies it to the UK through an authorised distribution network. That network ends at pharmacies and dispensing services that hold the correct regulatory permissions. If a pen did not travel that route, it cannot be verified as genuine, a point the MHRA has flagged repeatedly in public safety communications about counterfeit weight-loss pens reported via the Yellow Card scheme. Knowing the manufacturer is the first step; knowing the supply chain is the second.

For a deeper look at the semaglutide molecule itself and how Novo Nordisk developed it, the semaglutide overview on this site covers the science in plain language.

What Novo Nordisk actually put inside the pen

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating; it signals to the brain that you've had enough, slows gastric emptying and nudges the pancreas to manage blood sugar. The molecule in Wegovy is a synthetic version engineered to last a full week in the body rather than the few minutes a naturally released GLP-1 pulse would survive. Novo Nordisk's chemists attached a fatty acid chain to make it bind to blood proteins and resist breakdown. That structural choice is patented, which is why no other company can sell the identical product under a different name in the UK.

The injection itself comes in a pre-filled pen. The licensed UK maintenance pathway runs from 0.25 mg up through 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, each step supervised by a prescriber. Novo Nordisk received MHRA approval on 14 April 2026 for a dedicated single-dose 7.2 mg pen, representing a higher maintenance option for eligible adults with obesity (BMI 30 or above). Whether a specific dose or pen format is available at any given moment is confirmed at consultation, supply snapshots change, and payday week in January tends to bring a surge in requests that can affect stock across every pharmacy.

If you are curious whether your body already makes something similar to what Novo Nordisk synthesised, there is a useful explanation on our page about whether your body produces semaglutide naturally.

What NICE and the NHS say about Wegovy, and what that means practically

Novo Nordisk sought and received a NICE recommendation for Wegovy in March 2023 (NICE TA875), but the conditions attached are strict: NHS use is recommended for a maximum of two years, within a specialist weight management service, for adults with a BMI of 35 or above and at least one weight-related condition. Ethnic-background BMI thresholds are typically 2.5 kg/m² lower. NHS waiting lists for those services can stretch considerably, and not everyone meets the criteria.

A private prescription from a regulated online pharmacy is the alternative for people outside those NHS parameters or unwilling to wait. The NICE appraisal of semaglutide (TA875) sets out the full recommendation, including when a prescriber should consider stopping if weight loss is insufficient. It is worth reading if you want to understand exactly how the NHS frames the medicine's benefit.

Pricing context is covered separately on the Wegovy cost page, which explains what a legitimate private prescription typically includes and why the lowest listed price is rarely the most useful comparison. The semaglutide products page also maps out the different branded medicines Novo Nordisk produces, including Ozempic, which is licensed for type 2 diabetes rather than weight management, the distinction matters legally and clinically.

How to confirm your Wegovy comes from a legitimate source

Because Novo Nordisk is the sole producer of genuine Wegovy, any pen that did not arrive through a pharmacy you can verify is an unknown quantity. If you want to understand who Wegovy is produced by and why that single-manufacturer status matters for authenticity, it is worth reading before you buy. The GPhC maintains a public register of licensed pharmacies; you can check any service at pharmacyregulation.org/registers in under a minute. A pharmacy on that register has met dispensing standards and is accountable to regulators. One that is not listed has no such accountability.

Red flags worth knowing: a seller offering semaglutide pens without asking for a consultation or medical history, prices dramatically below what other regulated pharmacies charge, or discount codes attached to a prescription medicine. Genuine Wegovy pens dispensed through licensed channels will always be preceded by clinical assessment. The MHRA has warned that counterfeit pens have contained substances ranging from nothing active to insulin, the risk is not theoretical. Our page on where Wegovy is produced explains the specific licensed facilities involved, which can help you judge whether the packaging and documentation you receive look consistent with the genuine article.

At nume, every prescription is reviewed by a GPhC-registered prescriber, not automated software, before anything is dispensed. If you'd like to understand the wider treatment landscape before deciding anything, the weight-loss treatment overview covers your options in full. When you are ready to take the next step, start your free consultation and a prescriber will assess whether Wegovy is appropriate for you.